RxDoctor Payments Data

Melissa Chapel

Family · Augusta, GANPI 1407224819

Payments from drug & device makers

$3,424in general payments, 2019–2025

Across 153 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$973
  • Scilex Pharmaceuticals Inc.$382
  • IBSA Pharma Inc.$307
  • Collegium Pharmaceutical, Inc.$228
  • Globus Medical$197
  • Azurity Pharmaceuticals, Inc.$159
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,40399%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,424 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$8,642
Medicare patients
66
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine28$5,754
Pregabalin305$5,428
Gabapentin306$3,355
Lidocaine37$3,292
Tramadol Hcl158$2,369
Naloxone Hcl31$2,219
Tizanidine Hcl206$1,659
Tramadol Hcl ErTramadol Hcl27$1,617
Duloxetine Hcl82$913
Methylprednisolone125$770
Cyclobenzaprine Hcl82$727
Diclofenac Sodium54$663
Dexamethasone51$629
Celecoxib22$522
Methocarbamol79$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine$36$5,75428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →